跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 50 条关于
“Rigel”
全部
50
临床试验
16
药物
9
机构
3
资讯
22
11个月前
Rigel Pharmaceuticals Reports Strong Growth Across Oncology Portfolio with 44% Revenue Increase
2个月前
Rigel Pharmaceuticals Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer to Drive Oncology Pipeline
去年
Rigel Pharmaceuticals Reports Strong Growth with TAVALISSE and REZLIDHIA in 2024, Expands Global Reach
去年
FDA Grants Orphan Drug Designation to Rigel's R289 for Myelodysplastic Syndromes
去年
FDA Grants Fast Track Designation to Rigel's R289 for Lower-Risk Myelodysplastic Syndrome
11个月前
Rigel Pharmaceuticals Advances R289 Phase 1b Trial for Lower-Risk MDS with First Dose Expansion Patient
去年
Rigel Pharmaceuticals Unveils Promising Final Data from GAVRETO and REZLIDHIA Clinical Trials at ASCO and EHA 2025
2年前
Rigel Pharmaceuticals Initiates Phase Ib/II Trial of REZLIDHIA Combination Therapy for mIDH1 AML
去年
Rigel's Fostamatinib Enrolls First Patient in Phase I Sickle Cell Disease Trial
去年
RIPK1 Inhibitor Pipeline Shows Promise Despite Sanofi Setback in Multiple Sclerosis
第 1 页,共 3 页
上一页
下一页